Inhalation & Respiratory Drug Delivery 2020 conference

Conference website: www.irdd-summit.com/
 

The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis. The event highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

 

On 28 & 29 May 2020, New York (USA) will host the 2nd Annual IRDD Summit 2020 (Inhalation & Respiratory Drug Delivery 2020 conference). This year’s event is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market. The agenda also features key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy.

 

A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA) found America’s biopharmaceutical companies are developing about 130 new medicines for the millions of patients affected by respiratory diseases: chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, and asthma. These medicines represent critical advancements in respiratory care and improving quality of life. In addition to the drugs, devices delivering those products are being designed to improve the quality of life for an aging population, children, and those who tend not to comply to dosing regimens because they don’t know how to use the device. The global respiratory care devices market is expected to exceed more than $24 billion by 2022,2 and could exceed $33 billion by 2023.

 

The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis. The event highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

 

Contact us

Diogo Ribeiro

Tel:+351 915 239 640

Email: diogo.ribeiro@epmgroup.org